Shun J Li

age ~86

from Fredericksburg, VA

Get Report

Also known as:

Connected to:

Shun Li Phones & Addresses

Stable Insulin Formulations
view source
US Patent:

6551992, Apr 22, 2003
Filed:

Nov 29, 1999
Appl. No.:

09/450794
Inventors:

Michael Rosario DeFelippis - Indianapolis IN
Michael Allen Dobbins - Lebanon IN
Bruce Hill Frank - Indianapolis IN
Shun Li - Indianapolis IN
Dawn Marie Rebhun - Indianapolis IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K 3828
US Classification:

514 3, 514866, 514 4, 530303, 530304, 530300
Abstract:

The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.

Stable Insulin Formulations
view source
US Patent:

6906028, Jun 14, 2005
Filed:

Oct 3, 2002
Appl. No.:

10/264176
Inventors:

Michael Rosario DeFelippis - Indianapolis IN, US
Michael Allen Dobbins - Lebanon IN, US
Bruce Hill Frank - Indianapolis IN, US
Shun Li - Indianapolis IN, US
Dawn Marie Rebhun - Indianapolis IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K038/28
US Classification:

514 3, 514 4, 514 12, 530303, 530304, 530305
Abstract:

The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.

Muteins Of Fibroblast Growth Factor 21
view source
US Patent:

7491697, Feb 17, 2009
Filed:

Dec 1, 2004
Appl. No.:

10/579510
Inventors:

John Michael Beals - Indianapolis IN, US
Christopher Carl Frye - Bargersville IN, US
Wolfgang Glaesner - Indianapolis IN, US
Shun Li - Carmel IN, US
Radhakrishnan Rathnachalam - Carmel IN, US
Jing Shang - Fishers IN, US
Beth Ann Strifler - Brownsburg IN, US
Radmila Micanovic - Indianapolis IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07K 14/50
A61K 38/18
US Classification:

514 12, 514 2, 530399
Abstract:

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Muteins Of Fibroblast Growth Factor 21
view source
US Patent:

20090118190, May 7, 2009
Filed:

Jan 6, 2009
Appl. No.:

12/349119
Inventors:

John Michael Beals - Indianapolis IN, US
Christopher Carl Frye - Bargersville IN, US
Wolfgang Glaesner - Indianapolis IN, US
Shun Li - Carmel IN, US
Radhakrishnan Rathnachalam - Carmel IN, US
Jing Shang - Fishers IN, US
Beth Ann Strifler - Brownsburg IN, US
Radmila Micanovic - Indianapolis IN, US
International Classification:

A61K 38/18
C07K 14/50
US Classification:

514 12, 530399
Abstract:

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Pegylated Insulin Lispro Compounds
view source
US Patent:

20090312236, Dec 17, 2009
Filed:

Jun 9, 2009
Appl. No.:

12/481111
Inventors:

John Michael Beals - Indianapolis IN, US
Brandon Doyle - Indianapolis IN, US
Ryan John Hansen - Riverton UT, US
Shun Li - Carmel IN, US
Sean Shirani - Carmel IN, US
Lianshan Zhang - Carmel IN, US
International Classification:

A61K 38/28
C07K 14/62
A61P 3/10
C07K 1/00
US Classification:

514 3, 530303, 530345
Abstract:

The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.

Pegylated Insulin Lispro Compounds
view source
US Patent:

20110105392, May 5, 2011
Filed:

Jun 9, 2009
Appl. No.:

12/997254
Inventors:

John Michael Beals - Indianapolis IN, US
Brandon Lee Doyle - Indianapolis IN, US
Ryan John Hansen - Riverton UT, US
Shun Li - Carmel IN, US
Shahriar Shirani - Carmel IN, US
Lianshan Zhang - West Windsor NJ, US
Assignee:

ELI LILLY AND COMPANY - Indianapolis IN
International Classification:

A61K 38/28
C07K 14/62
A61P 3/10
US Classification:

514 63, 530303
Abstract:

The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.

Stable Insulin Formulations
view source
US Patent:

60340541, Mar 7, 2000
Filed:

Jun 11, 1998
Appl. No.:

9/096247
Inventors:

Michael Rosario DeFelippis - Indianapolis IN
Michael Allen Dobbins - Lebanon IN
Bruce Hill Frank - Indianapolis IN
Shun Li - Indianapolis IN
Dawn Marie Rebhun - Indianapolis IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

A61K 3828
US Classification:

514 4
Abstract:

The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.